Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Buy Kotak Mahindra Bank; target of Rs 470: Motilal Oswal
Motilal Oswal is bullish on Kotak Mahindra Bank recommended buy rating on the stock with a target price of Rs 470 in its research report dated May 03, 2026.
Buy Kotak Mahindra Bank; target of Rs 480: Prabhudas Lilladher
Prabhudas Lilladher is bullish on Kotak Mahindra Bank has recommended buy rating on the stock with a target price of Rs 480 in its research report dated May 03, 2026.
HDFC Mutual Fund sells shares worth Rs 358 crore in Sundram Fasteners
As of December 2025, HDFC Mutual Fund through HDFC NIFTY500 Multicap 50:25:25 Index Fund held 7.62 percent equity stake in the TVS Group company.
Sensex Today | Stock Market Live: Sensex jumps 880 pts, Nifty above 24,250; all sectors rally
Sensex Today | Stock Market LIVE Updates: Maruti Suzuki, Adani Ports, Bajaj Auto, HUL, Tata Consumer were among major gainers on the Nifty, while losers were Kotak Mahindra Bank, Dr Reddy's Labs, ONGC, Eternal and Adani Enterprises. All the sectoral indices are trading in the green with auto, FMCG, realty, power, telecom up 1% each. Nifty Midcap and Smallcap indices up 0.7% each.
US Steps In to Escort Ships in Hormuz | Oil Near $108 | Kotak Bank Steady | Opening Bell
Markets kick off the week with global tensions in focus as US President Donald Trump announces “Project Freedom” to escort stranded vessels through the Strait of Hormuz. Iran calls the US response to its 14-point proposal unacceptable, keeping geopolitical risks elevated and pushing Brent crude near $108. US markets ended higher on Friday, with the Dow Jones Industrial Average, S&P 500, and NASDAQ Composite gaining up to 1.6%, supported by strong earnings from Exxon Mobil, Chevron, and Estée Lauder. Economic data remains mixed, with steady manufacturing activity and a rise in consumption. Back home, Kotak Mahindra Bank reports a stable quarter, while GIFT Nifty suggests a positive start for Indian markets. Investors also keep a close watch on state election results for further cues.
Buy Kotak Mahindra Bank; target of Rs 480: Prabhudas Lilladher
Prabhudas Lilladher is bullish on Kotak Mahindra Bank has recommended buy rating on the stock with a target price of Rs 480 in its research report dated July 01, 2026.
Kotak Mahindra Bank stock falls 2.6%, top Nifty loser; analysts hail Q4 results margin gains, but flag RoE lag
Kotak Mahindra Bank’s asset quality improved during the quarter, with gross non-performing assets easing sequentially, while provisions declined sharply, supporting earnings.
ADIA sells 2.3% stake in Lenskart for Rs 1,960 crore to 19 investors including Morgan Stanley, Goldman Sachs, SBI MF
Lenskart Solutions Block Deals: Kotak Mahindra Asset Management was the largest buyer, picking up 1.27 crore shares (0.7 percent stake) for Rs 626 crore.
Newly-listed Knack Packaging shares jump up to 10% after Bank of India Mutual Fund acquires 0.57% stake
Shares of newly-listed packaging solutions provider Knack Packaging surged up to 10% on Friday, trading at Rs 215.23 on the National Stock Exchange, following a domestic institutional purchase.
Stocks to Watch Today: Maruti Suzuki, Aster DM Health, IndiaMART, RailTel Corporation, ACC, Eveready Industries, Avenue Supermarts in focus on 4 May
Stocks to Watch, 04 Apr: Stocks like Adani Enterprises, Kotak Mahindra Bank, Avenue Supermarts, ACC, Sundram Fasteners, ESAF Small Finance Bank, Capri Global Capital, Eveready Industries India, RailTel Corporation of India, IndiaMART InterMESH, Sona BLW Precision Forgings, and Aster DM Healthcare will release their quarterly earnings on April 4.
Taking Stock: Nifty ends near 23,150 in volatile trade; pharma, private banks rally
ICICI Bank, Kotak Mahindra Bank, Grasim, M&M, JSW Steel were among top gainers on the Nifty, while losers were Infosys, HCL Tech, Adani Ports, Trent, Eternal.
Kotak Mahindra MF buys Rs 612 crore worth Emcure shares from Bain Capital, promoter sells 2.8% stake in Ajanta Pharma
BC Investments held 3.87 percent stake in Emcure Pharmaceuticals as of March 2026.